Deutsche Bank Ag\ Terns Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 542,846 shares of TERN stock, worth $2.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

542,846

Previous 97,178 458.61%

Holding current value

$2.76 Million

Previous $661,000 584.87%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$6.49 - $10.8 $2.89 Million - $4.81 Million	445,668 Added 458.61%	542,846 $4.53 Million
Q2 2024 Aug 14, 2024	BUY	$4.54 - $8.2 $333,808 - $602,913	73,526 Added 310.87%	97,178 $661,000
Q1 2024 May 15, 2024	BUY	$4.86 - $8.19 $3,227 - $5,438	664 Added 2.89%	23,652 $155,000
Q4 2023 Feb 14, 2024	BUY	$3.37 - $6.86 $1,816 - $3,697	539 Added 2.4%	22,988 $149,000
Q3 2023 Nov 09, 2023	BUY	$4.7 - $8.55 $19,368 - $35,234	4,121 Added 22.48%	22,449 $112,000
Q2 2023 Aug 14, 2023	BUY	$7.35 - $13.29 $134,710 - $243,579	18,328 New	18,328 $160,000
Q2 2022 Aug 11, 2022	SELL	$1.5 - $3.0 $12,049 - $24,099	-8,033 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.83 - $6.7 $2,484 - $5,882	-878 Reduced 9.85%	8,033 $24,000
Q4 2021 Feb 11, 2022	BUY	$5.65 - $10.73 $2,486 - $4,721	440 Added 5.19%	8,911 $63,000
Q3 2021 Nov 04, 2021	BUY	$7.22 - $13.46 $18,605 - $34,686	2,577 Added 43.72%	8,471 $88,000
Q2 2021 Aug 11, 2021	BUY	$12.26 - $22.0 $5,002 - $8,976	408 Added 7.44%	5,894 $72,000
Q1 2021 May 13, 2021	BUY	$17.13 - $27.25 $93,975 - $149,493	5,486 New	5,486 $120,000

Others Institutions Holding TERN

# of Institutions

168

Shares Held

78.3M

Call Options Held

580K

Put Options Held

454K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $191M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account